Free Trial

Celldex Therapeutics (CLDX) Competitors

$36.76
-0.81 (-2.16%)
(As of 07/19/2024 ET)

CLDX vs. NTLA, VIVO, RIOT, HSKA, EXAS, IONS, RGEN, HALO, EXEL, and MDGL

Should you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Riot Platforms (RIOT), Heska (HSKA), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), Repligen (RGEN), Halozyme Therapeutics (HALO), Exelixis (EXEL), and Madrigal Pharmaceuticals (MDGL).

Celldex Therapeutics vs.

Celldex Therapeutics (NASDAQ:CLDX) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation.

Celldex Therapeutics presently has a consensus price target of $62.17, suggesting a potential upside of 69.11%. Intellia Therapeutics has a consensus price target of $69.00, suggesting a potential upside of 175.12%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Intellia Therapeutics
0 Sell rating(s)
4 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, Intellia Therapeutics had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 10 mentions for Intellia Therapeutics and 6 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.71 beat Intellia Therapeutics' score of 0.26 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celldex Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Intellia Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Celldex Therapeutics received 181 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. Likewise, 75.06% of users gave Celldex Therapeutics an outperform vote while only 69.51% of users gave Intellia Therapeutics an outperform vote.

CompanyUnderperformOutperform
Celldex TherapeuticsOutperform Votes
605
75.06%
Underperform Votes
201
24.94%
Intellia TherapeuticsOutperform Votes
424
69.51%
Underperform Votes
186
30.49%

Intellia Therapeutics has a net margin of 0.00% compared to Celldex Therapeutics' net margin of -2,385.57%. Celldex Therapeutics' return on equity of -29.55% beat Intellia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex Therapeutics-2,385.57% -29.55% -27.66%
Intellia Therapeutics N/A -45.35%-37.40%

Celldex Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500.

Celldex Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$6.07M399.03-$141.43M-$2.85-12.90
Intellia Therapeutics$36.28M66.69-$481.19M-$5.36-4.68

88.8% of Intellia Therapeutics shares are held by institutional investors. 3.8% of Celldex Therapeutics shares are held by insiders. Comparatively, 3.0% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Celldex Therapeutics beats Intellia Therapeutics on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLDX vs. The Competition

MetricCelldex TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$2.42B$3.06B$5.30B$8.23B
Dividend YieldN/A0.70%2.74%3.95%
P/E Ratio-12.90169.62155.0818.12
Price / Sales399.0367.872,148.7476.08
Price / CashN/A17.6236.1033.93
Price / Book4.053.724.864.42
Net Income-$141.43M$30.88M$111.86M$216.15M
7 Day Performance-7.64%1.54%-0.66%-0.11%
1 Month Performance3.00%3.36%7.55%5.61%
1 Year Performance-0.76%-26.66%4.33%1.32%

Celldex Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NTLA
Intellia Therapeutics
4.3866 of 5 stars
4.39 / 5 stars
$25.08
-3.9%
$69.00
+175.1%
-42.1%$2.42B$36.28M-4.68526Analyst Revision
VIVO
Meridian Bioscience
0 of 5 stars
0.00 / 5 stars
$33.97
flat
N/AN/A$1.50B$333.02M35.02702Analyst Forecast
RIOT
Riot Platforms
3.1377 of 5 stars
3.14 / 5 stars
$12.03
+9.9%
$17.01
+41.4%
-34.9%$3.47B$280.70M13.83534News Coverage
HSKA
Heska
0 of 5 stars
0.00 / 5 stars
$119.99
flat
N/AN/A$1.31B$257.31M-62.17808Analyst Forecast
EXAS
Exact Sciences
4.4072 of 5 stars
4.41 / 5 stars
$46.81
-1.6%
$85.80
+83.3%
-50.7%$8.64B$2.50B-35.466,600Analyst Forecast
Analyst Revision
News Coverage
IONS
Ionis Pharmaceuticals
4.3655 of 5 stars
4.37 / 5 stars
$47.82
+1.0%
$60.07
+25.6%
+16.7%$6.98B$788M-17.91927Analyst Forecast
Insider Selling
Short Interest ↑
Analyst Revision
News Coverage
RGEN
Repligen
4.6632 of 5 stars
4.66 / 5 stars
$123.81
-3.0%
$194.00
+56.7%
-21.4%$6.92B$638.76M495.261,783Analyst Revision
News Coverage
Positive News
HALO
Halozyme Therapeutics
4.8213 of 5 stars
4.82 / 5 stars
$54.04
-0.5%
$57.25
+5.9%
+26.9%$6.88B$829.25M22.33373Analyst Forecast
EXEL
Exelixis
4.9384 of 5 stars
4.94 / 5 stars
$22.60
+0.2%
$26.13
+15.6%
+13.7%$6.85B$1.85B35.311,310Short Interest ↓
Positive News
MDGL
Madrigal Pharmaceuticals
4.5545 of 5 stars
4.55 / 5 stars
$287.24
+2.9%
$348.50
+21.3%
+34.7%$6.12BN/A-12.44376Analyst Forecast
News Coverage

Related Companies and Tools

This page (NASDAQ:CLDX) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners